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ABSTRACT 
Allergy is a complex biological response mediated by several different cell types 
including B lymphocytes, T lymphocytes and eosinophils. From clinical observations 
it is well-known that microbial infections, in particular viruses, can cause 
exacerbation of allergic rhinitis and asthma. The underlying mechanisms are still far 
from understood but recent data indicate that an activation of the immune system 
via pattern-recognition receptors (PRRs) including NOD-like receptors (NLRs), RIG-
like receptors (RLRs) and Toll-like receptors (TLRs) might play a role. These receptors 
recognize invading microorganisms and enable them to interact directly with an 
ongoing inflammatory response. In addition, the receptors have been linked to 
atopic disorders such as allergic rhinitis. Today, allergen-specific immunotherapy is 
the only treatment that in addition to relieving symptoms also changes the progress 
of the underlying allergic airway disease. This therapy is traditionally administered 
through subcutaneous injections during three to four years but recently, 
intralymphatic allergen-specific immunotherapy (ILIT) emerged as an effective and 
less time-consuming alternative. 
The aim of this thesis is to investigate novel targets of potential use for treatment of 
airway inflammation with special focus on PRRs and ILIT. 
The first part of the thesis (P A P E R S  I - I II ) is focused on NLRs and RLRs in human 
leukocytes. A range of NLRs and RLRs were detected at mRNA and protein levels. 
Their expression in B lymphocytes was generally higher in cells derived from 
peripheral blood than in cells from tonsils. In T cells, a differentiated expression was 
seen among CD4+ and CD8+ tonsillar cells. Stimulation with cognate ligands in 
combination with triggering of the B cell receptor (via IgM or IgD) or the T cell 
receptor (CD3/CD28) promoted lymphocyte activation as shown by enhanced 
proliferation, up-regulated expression of cell-surface markers, prolonged survival 
and secretion of cytokines. Concomitant stimulation via the NLR and TLR systems 
synergistically enhanced the proliferative responses of B cells. Altogether this 
indicates that lymphocytes have the ability to recognize pathogens via the PRR 
system and it supports the idea of a role for innate receptors also in the adaptive 
branch of the immune system.  
Eosinophils expressed both NLRs and RLRs and stimulation with the NOD1 and 
NOD2 ligands promoted activation as manifested by the release of cytokines, 
enhanced survival, regulated expression of cell-surface markers and induced 
chemotactic migration. These events appeared to be related to the NF-κB pathway. 
Stimulation with the Th2-like cytokines IL-5 and GM-CSF augmented NLR-mediated 
activation. These findings suggest the NLRs to be a new activation pathway for 
eosinophils and possibly a link between respiratory infections and allergic 
exacerbations. 
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In the second part of the thesis (P A P E R S  IV -V ), the clinical and cellular effects of 
ILIT are evaluated. Actively treated patients exhibited a clear improvement of their 
seasonal allergic symptoms as well as their nasal symptoms upon allergen challenge. 
The treatment increased the levels of allergen-specific IgE and decreased nasal 
inflammatory responses. On a cellular level, activation of CD4+ T cells and 
granulocytes was induced along with reduced Th2 and regulatory T lymphocyte 
activity. These findings appear to confirm ILIT as a safe and effective therapy for 
allergic rhinitis and reveal new insights on the cellular mechanisms underlying its 
beneficial effects. 
In summary, this thesis demonstrates a role for PRRs in lymphocytes and 
eosinophils and that ILIT is a safe and effective route that can be used for treating 
patients with allergic airway disorders. In the future, we hope that these findings 
can be used in the development of new and more effective treatment strategies for 
airway inflammation. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Människans immunförsvar brukar vanligtvis indelas i ett medfött (ospecifikt) och ett 
förvärvat (specifikt) försvar. Det medfödda immunförsvaret känner omedelbart igen 
strukturer som är främmande för kroppen och detta försvar medieras bl.a. av 
eosinofiler som har en viktig roll i bekämpandet av parasiter men som även 
förknippas med astma och allergi. Det förvärvade immunförsvaret utvecklas till följd 
av infektion och utgörs av B- och T-celler som producerar antikroppar och 
inflammatoriska ämnen som kan bekämpa inträngande mikroorganismer. I 
avhandlingens första del har vi studerat kopplingen mellan medfödd och förvärvad 
immunitet vid igenkänningen av bakterier och virus, medan den andra halvan 
fokuserar på immunförsvarets betydelse vid allergivaccination.  
Det är välkänt att infektioner, framförallt av virus, kan försämra såväl allergisk rinit 
(hösnuva) som astma, men hur detta i detalj går till är fortfarande okänt. Mycket 
talar dock för att s.k. patogen-igenkännande receptorer kan ha en betydande roll i 
denna process genom sin förmåga att aktivera det medfödda försvaret som i sin tur 
drar igång det förvärvade svaret. Dessa receptorer kan delas in i olika familjer och 
däribland finns de NOD-lika och RIG-lika receptorerna. När dessa receptorer känner 
igen bakterier respektive virus startar olika processer i cellen vilket leder till 
frisättning av ämnen som orsakar inflammation. De NOD-lika och RIG-lika 
receptorerna har nyligen blivit upptäckta och ganska lite känt om vart de finns och 
vad deras funktion är. Målet med avhandlingens första del (A R B E T E  I - I II ) var att 
kartlägga förekomst och funktion av NOD-lika och RIG-lika receptorer i B-celler, T-
celler och eosinofiler.  
För att undersöka detta isolerades celler från blod och halsmandlar. Förekomst av 
de NOD-lika och RIG-lika receptorerna analyserades i de olika celltyperna och 
cellerna odlades med eller utan olika bakterie- och virusstrukturer med känd 
förmåga att aktivera NOD-lika och RIG-lika receptorer. Hur cellerna reagerade (dvs. 
deras funktion) registrerades. Vi fann att NOD-lika och RIG-lika receptorer var 
vanligt förekommande i B-celler, T-celler och eosinofiler och att stimulering med 
mikrobiella strukturer aktiverade cellerna vilket resulterade i inflammatoriska 
reaktioner. I eosinofiler kunde vi också visa att inflammatoriska ämnen som är 
karaktäristiska för allergiker gör att cellerna reagerar mer uttalat på bakteriella 
strukturer.  
Detta är första gången som närvaro av NOD-lika och RIG-lika receptorer visas i B-
celler, T-celler och eosinofiler vilket innebär att receptorer som tillhör det medfödda 
immunförsvaret finns på celler som tillhör såväl det medfödda (eosinofiler) som det 
förvärvade immunförsvaret (B-celler och T-celler). Detta fynd suddar ut gränsen 
mellan immunförsvarets två grenarna då det har ansetts att det medfödda 
immunförsvarets igenkänning av mikroorganismer är en förutsättning för att det 
förvärvade immunsvaret ska engageras. Vidare verkar det som om individens 
allergiska status påverkar hur eosinofiler reagerar vid bakterie- och virusinfektion, 
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vilket skulle kunna vara en bidragande orsak till att allergiska besvär kan förvärras 
vid t.ex. förkylning. 
Det har visat sig att fel i de NOD-lika och RIG-lika receptorerna kan leda till 
utveckling av allergi och astma. Vid allergi reagerar immunförsvaret mot ofarliga 
ämnen i omgivningen (t.ex. pollen, födoämnen och husdjur) och utsöndrar då olika 
inflammatoriska substanser som kan ge upphov till symptom som nästäppa, 
rinnande ögon och hosta. Det finns flera varianter av symptomlindrande behandling 
men endast allergivaccination påverkar sjukdomens vidare utveckling. Förenklat kan 
man säga att allergivaccination manipulerar immunförsvaret så att kroppens 
reaktioner mot allergenet minskar. Allergivaccination ges vanligtvis med sprutor i 
armen, men då det normalt krävs injektioner var sjätte vecka under 3-5 år, avstår 
många patienter från behandling. Nyligen har det framkommit data som tyder på 
att tre sprutor, givna direkt i en lymfkörtel i ljumsken med en månads mellanrum, 
kan vara lika effektivt som 3-5 års traditionell behandling. Dock vet man inte idag 
om denna behandlingsmetod är helt säker för patienten eller vad som händer i 
kroppen när man behandlar allergi på detta sätt. Därför behöver den nya 
behandlingen utvärderas innan den kan erbjudas som alternativ till traditionell 
allergivaccination. 
I avhandlingens andra del (A R B E T E  IV -V ) har vi utvärderat om det är säkert att 
behandla pollenallergiska patienter med allergen-injektioner direkt in i en 
lymfkörtel. Vi fann att denna behandlingsmetod är säker för patienten och att den 
inte orsakar fler biverkningar än traditionell allergivaccination. Efter genomförd 
behandling rapporterade patienterna färre allergiska symtom när de sprayades med 
allergen i näsan och de upplevde en klar förbättring av sina allergisymtom under 
följande pollensäsong. Därefter undersökte vi om denna behandlingsmetod kan 
förändra immunförsvaret på liknande sätt som när vaccinationen ges via sprutor i 
armen. Resultaten tyder på att behandlingen är associerad med förändringar i 
cellernas reaktivitet, inflammatoriska svar och immunförsvarets sammansättning av 
celler, vilket stämmer väl överens med vad som sker vid traditionell 
allergivaccination. Detta tyder på att sprutor som ges direkt in en lymfkörtel i 
ljumsken kan vara ett tidssparande och effektivt sätt för behandling av allergiska 
besvär.  
Sammantaget så hoppas vi att det som framkommit i denna avhandling i framtiden 
ska kunna användas som underlag vid utveckling av nya och mer effektiva 
behandlingsstrategier för sjukdomar i luftvägarna. 
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NF-κB Nuclear factor- κB 
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PRR Pattern-recognition receptor 
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AIMS  
The aim of this thesis project is to investigate novel targets of potential use for 
treatment of airway inflammation with special focus on pattern-recognition 
receptors and intralymphatic allergen-specific immunotherapy. More specifically, 
the aims are: 
 
¾ To characterize expression and functional activities of NOD-like receptors in 
human tonsillar and blood-derived B cells (P A P E R  I ). 
 
¾ To create an expression profile for NOD-like receptors and RIG-like receptors in 
human tonsillar T cells and to analyze their functional relevance (P A P E R  I I ). 
 
¾ To characterize the expression of NOD-like receptors and RIG-like receptors in 
human eosinophils and to investigate their potential role in microbe-induced 
exacerbations of allergic airway inflammation (P A P E R  II I ). 
 
¾ To evaluate the safety and clinical effects of intralymphatic allergen-specific 
immunotherapy for treatment of pollen-induced allergic rhinitis (P A P E R  IV ). 
 
¾ To explore cellular changes induced by intralymphatic allergen-specific 
immunotherapy and to assess the mechanisms involved (P A P E R  V ). 
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INTRODUCTION 
THE IMMUNE SYSTEM  
The immune system consists of numerous cells, tissues and mediators that defend 
the host from potentially harmful substances and pathogens. However, the ability 
to eliminate foreign structures comes with a risk of misdirected immune responses 
towards innocuous antigens, which might lead to the development of allergic and 
autoimmune diseases 1, 2. 
The vertebrate immune system is often described as two separate branches; the 
innate and the adaptive immunity. However, accumulating evidence point to a close 
interaction between the two arms and it is now apparent that efficient protection 
against pathogens is mediated via cooperation of the blunt but rapid innate immune 
response and the highly specific adaptive immune response. In this thesis, the two 
branches will be presented separately and focus will be on cells and receptors of 
importance to the present work (as highlighted in F I G U R E  1 ). 
 
 
F I G U R E  1 .  Schematic overview of the innate and adaptive immunity with cells and receptors 
of importance to the thesis highlighted. 
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INNATE  I MM UNI TY  
The innate immune system provides a non-specific defense that is ready to mobilize 
within minutes after the first signs of danger. The first line of defense is provided by 
physical and chemical barriers that include epithelial surfaces, antimicrobial 
peptides and the complement system. If the pathogen is able to circumvent this 
initial defense, then the innate immune cells, including granulocytes, monocytes, 
macrophages, natural killer cells and dendritic cells become activated 2, 3. These cells 
have the ability to destroy the invading pathogen, to call the attention of 
phagocytes to the microbe and to activate the adaptive branch of the immune 
system. 
To be able to respond immediately to invading pathogens, the cells of the innate 
immune system express pattern-recognition receptors (PRRs). They recognize 
microbial motifs termed pathogen-associated molecular pattern (PAMPs), which are 
highly conserved components of the microorganism not present on mammalian 
cells, or endogenous molecules produced by injured or dying cells called danger-
associated molecular patterns (DAMPs) 1, 2, 4.  
 
PATT ERN-R EC O GN ITI O N R EC EPT OR S  
Germline-encoded PRRs constitute an essential part of the innate immune system 
allowing recognition of invading microorganisms. To date, the human PRR family 
consists of at least three receptor families, including Toll-like receptors (TLRs), NOD-
like receptors (NLRs) and RIG-like receptors (RLRs), which recognize different classes 
of pathogens, including bacteria, viruses and fungi. To ensure effective detection 
and clearance of infections, the PRRs are positioned in different cellular 
compartments. The TLRs are located at the cell surfaces and in the endosomes, 
whereas the NLRs and RLRs are found in the cytosol 5-8. A schematic overview of the 
innate immune receptors and their cognate ligands is presented in F I G U R E  2.  
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F I G U R E  2 .  Schematic overview of Toll-like receptors, NOD-like receptors and RIG-like 
receptors and their cognate ligands. 
 
TOLL-LI KE RE CEP TO RS   
The first PRRs to be discovered were the TLRs and therefore these receptors have 
been most extensively studied among the PRRs. Today, the human TLRs consist of 
10 members and they are found both extracellularly (TLR1, TLR2, TLR4, TLR5, TLR6 
and TLR10) and intracellularly (TLR3, TLR7, TLR8 and TLR9).  
In general, the receptors positioned at the cell surface are involved in the 
recognition of bacterial cell wall components such as lipoproteins (TLR1, TLR2 and 
TLR6), lipopolysaccharide (LPS, TLR4) and flagellin (TLR5). In contrast, the 
intracellular TLRs primarily respond to viral components including dsRNA (TLR3), 
ssRNA (TLR7 and TLR8) and DNA-containing unmethylated CpG motifs (TLR9) 5, 8-11. 
TLRs are found in a range of cells and tissues, including eosinophils, neutrophils, 
monocytes, epithelial cells, lymphocytes, tonsils and nasal mucosa 12-18. 
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NOD-LI K E RE CEP TO RS  
The human NLR family consists of more than 20 members but the physiological 
functions of most members are poorly understood. Based on their N-terminal 
domains, the NLRs can be divided into three major subfamilies; caspase-activating 
and recruitment domain (CARD)-containing nucleotide-binding oligomerization 
domains (NODs), pyrine domain (PYD)-containing NACHT-, LRR- and PYRIN-domain 
containing proteins (NALPs) and baculovirus inhibitor repeat (BIR)-containing 
neuronal apoptosis inhibitor proteins (NAIPs). The NLRs are located within the 
cytosol where they primarily respond to bacterial infections and danger signals 5, 8, 
19. So far, cognate ligands have only been described for the best characterized 
members; NOD1, NOD2 and NALP3. 
NOD1 and NOD2 recognize peptidoglycan that is a major component of bacterial 
cell walls. More specifically, NOD1 senses the substructure J-D-glutamyl-meso 
diaminopimelic acid (iE-DAP) found in Gram-negative bacteria, whereas NOD2 
detects muramyl dipeptide (MDP) common to Gram-negative and Gram-positive 
bacteria.  
Both NOD1 and NOD2 recruit the kinase RIP2 upon activation, which subsequently 
activates NF-κB-dependent transcription of proinflammatory cytokines 10, 20. NALP3 
(also known as NLRP3) responds to danger signals released from injured or dying 
cells by forming caspase-1-activating protein complexes called inflammasomes, 
which eventually drives release of active IL-1β and IL-18. Additionally, recent studies 
have demonstrated a role for NALP3 in the recognition of aluminum salts (alum), 
commonly used as adjuvants in vaccines 21, 22. 
Expression of functional NLRs has been demonstrated in an emerging number of 
studies, but so far most of them have focused on innate immune cells including 
monocytes, dendritic cells and neutrophils 23-25. Information regarding these 
receptors in human eosinophils and lymphocytes has until now been lacking 26-28. 
 
RIG-LI KE RE CEP TO RS  
The RLRs represent the least characterized family of the innate immune receptors. 
To date, only three receptors have been identified; retinoic acid-inducible gene I 
(RIG-I), melanoma differentiation associated gene 5 (MDA-5) and laboratory of 
genetics and physiology 2 (LGP-2). In contrast to the antiviral TLRs located in the 
endosomes, the RLRs screen the cytoplasm and mediate responses against viruses 
replicating inside the cell. Recognition of viral components activates signaling 
mechanisms that eventually result in production of interferons (IFNs) 5, 8, 9, 19. 
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Both RIG-I and MDA-5 are capable of recognizing many different viruses. However, 
RIG-I preferably detects short dsDNA and ssRNA with a 5’-triphosphate moiety, 
whereas MDA-5 favors recognition of long dsRNA and poly(I:C) 29-31. The role of LGP-
2 is still under investigation as no ligand has yet been identified, but it is thought to 
function as a regulator of RIG-I and MDA-5 responses 32. 
 
IM PL ICA TI ON S O F PRR S I N HU MAN D I SEA S E S  
Although PRRs function to protect the host from infection, an increasing number of 
studies have demonstrated that they are implicated in various immunological 
disorders, such as airway inflammation and allergic rhinitis 33, 34. In this context, 
especially TLR4 has gained interest through its involvement in the hygiene 
hypothesis. This hypothesis suggests that the reduced microbial burden during 
childhood in westernized countries causes a skewing of the immune system towards 
a Th2 profile that in turn can explain the increasing prevalence of allergic diseases 
seen during the last decades 35, 36. For the newly discovered cytosolic PRRs, such a 
connection has not been fully established but there is reason to suspect that these 
receptors could play a similar role. Although the field of NLR research is relatively 
new, polymorphisms in the genes encoding NOD1 (CARD4) and/or NOD2 (CARD15) 
have already been linked to allergic disorders 37-40. 
 
EO SIN OP HI L S  
Eosinophils are multifunctional leukocytes that mature in the bone marrow under 
the influence of IL-3, IL-5 and granulocyte macrophage-colony stimulating factor 
(GM-CSF) and they are thereafter released into the blood stream. Traditionally 
eosinophils are thought to be involved in innate immune defenses against parasitic 
helminthes, but they have been shown to play important roles in Th2-mediated 
immune responses and in the defense against viral and bacterial infections 41, 42. 
During allergic airway inflammation, the eosinophils are attracted to the airways by 
IL-8 and eotaxin and by regulating their expression of adhesion molecules such as 
CD11b and CD62L, they migrate from the circulation to the airways where their 
effector functions are exerted. 
Eosinophils are capable of releasing granule proteins including eosinophil cationic 
protein (ECP), eosinophil-derived neurotoxin (EDN), eosinophil peroxidase (EPO) and 
major basic protein (MBP). In addition, they can synthesize and secrete numerous 
cytokines, lipid mediators, leukotrienes and prostaglandins. This has attributed a 
role for eosinophils in allergic airway inflammation, airway hyperresponsiveness and 
airway remodeling 41, 43-45. An overview of the mechanisms by which eosinophils 
might affect the allergic airways is provided in F I G U R E  3 .  
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F I G U R E  3 .  Schematic overview of the possible involvement of eosinophils in allergic 
responses of the airways. 
 
AD APTI VE  IM MUNITY  
Most pathogenic infestations can be handled by the innate immune system, but if it 
fails to clear the infection, B and T lymphocytes of the adaptive immunity kick in. In 
contrast to the innate immunity recognizing generic patterns using a fixed set of 
PRRs, the adaptive immune system provides custom-made responses towards each 
specific pathogen. This highly sophisticated defense is created as a consequence of 
recombination of receptor genes during lymphocyte development, which generates 
receptors specific for virtually any antigen 46. 
 
LYM PH OC YT E ACT IV AT I ON  
Both B and T cells originate from stem cells in the bone marrow. The former stays in 
the bone marrow to mature, whereas the latter migrates to the thymus for further 
development. After maturation, lymphocytes are released to the circulation where 
they migrate and concentrate in secondary lymphoid organs such as tonsils and 
lymph nodes. Within these secondary lymphoid organs, the rare antigen-specific 
lymphocytes are brought together with antigen-presenting cells and this interaction 
with the innate immunity promotes the onset of the adaptive immunity 2, 47. 
The activation of lymphocytes is traditionally thought to depend on two distinct 
signals; a theory called the “two-model signal of lymphocyte activation”. The first 
signal is provided when lymphocytes recognize their corresponding antigen via their 
cell-bound B or T cell receptors (BCR or TCR, respectively). The BCR is made up by 
cell-bound antibodies that sense complex 3D structures, whereas the TCR responds 
to short linear peptides bound to MHC class I or II on antigen-presenting cells.  
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The antigen-binding to the BCR/TCR is stabilized by co-receptors such as CD19 on B 
cells and CD4 or CD8 on T cells. 
For B cells, the second activation signal can be provided by interaction between 
CD40 on the B lymphocytes and CD40L on T lymphocytes and in return, the B 
lymphocyte up-regulates CD80/CD86 that interacts with CD28 on the T cell, thereby 
providing its second activation signal 2, 3, 48, 49. The lymphocytes thereafter start to 
expand and participate in pathogen killing by producing antibodies and various 
mediators that in most cases promote clearance of the infection. The generation of 
sufficient amounts of antigen-specific cells takes approximately a week, which 
explains why the adaptive responses are slower than those of the innate immunity. 
However, upon a second pathogen-encounter, memory B and T lymphocytes will 
mount antigen-specific responses within a couple of days 46. 
 
B LY MP HO CY TE S  
The major role of B cells is to produce antibodies that are crucial in the defense 
against pathogens as they recognize, neutralize and target microbes for elimination, 
but the antibodies also function as BCRs. In addition to producing antibodies, B cells 
function as antigen-presenting cells and have the ability to secrete 
immunomodulatory cytokines that influence the polarization and activation of T 
lymphocytes and dendritic cells 50, 51.  After antigen-encounter and contact with T 
lymphocytes in the lymph nodes, the B cells become activated and differentiate into 
long-lived memory cells or antibody-secreting plasma cells 51, 52. Depending on the 
cytokines released in the lymph nodes, the B cells produce antibodies of a specific 
subclass, either Immunoglobulin A (IgA), IgD, IgE, IgG or IgM that all have different 
functions 1. For example, IgE is involved in the defense against parasites but also 
plays a pivotal role in initiation of allergic diseases, whereas IgG is implicated in 
immune responses against bacteria, viruses and fungi. An overview of the roles of B 
cells in immune responses is provided in F I G U R E  4 .  
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F I G U R E  4 .  Schematic overview of the roles of B cells in various immune responses. 
 
T LY MP HO CY TE S  
During maturation in the thymus, the T cells undergo rearrangement of TCRs and 
start to express either CD4 or CD8 co-receptors. Thereafter, they undergo positive 
and negative selection based on their affinity to MHC:self-peptide complexes. Cells 
that bind to MHC class I complexes become cytotoxic T lymphocytes (CTLs) 
expressing the CD8 co-receptor, whereas cells that recognize peptides on MHC class 
II differentiate to T helper cells (Th cells) expressing the CD4 co-receptor 2. An 
overview of the roles of T cells in immune responses is provided in F I G U R E  5 .  
 
 
F I G U R E  5 .  Schematic overview of the roles of T cells in various immune responses. 
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T HELP ER CE LLS  
Depending on the surrounding cytokine milieu and means of infection, CD4+ Th cells 
can differentiate into several different subsets, including Th1, Th2 and regulatory T 
cells 53. 
The Th1 and Th2 subsets were the first to be identified. Th1 cells produce for 
instance IFN-γ, which stimulates CTLs and promotes immunity against intracellular 
bacteria and viruses. Th2 cells secrete cytokines, including IL-4, IL-5 and IL-13 that 
are involved in clearance of extracellular pathogens but also mediate antibody 
production and isotype-switching of B cells 50, 53. The Th1 and Th2 subsets also have 
the ability to suppress each other. In various immunological diseases, an imbalance 
can be seen between Th1 and Th2 cells. Allergic disorders are associated with a 
predominance of Th2 cells and cytokines which can promote production of IgE in B 
cells and survival of eosinophils 50.  
Another Th subset is the regulatory T cells. This is a diverse population that can be 
characterized in many different ways depending on their expression of cell-surface 
markers and transcription factors. However, they all have the ability to balance 
immune responses by inducing antigenic tolerance in other immune cells. For 
example, this can be achieved by secretion of IL-10 that suppresses IgE production 
and promotes IgG4 secretion 50. 
 
CYTO TOXIC T C ELLS  
When a cell becomes infected by intracellular pathogens, the infested cell will 
present virus-derived peptides on MHC class I in order to call the attention of the 
immune system. These peptides will be discovered by CD8+ CTLs that upon 
recognition release cytotoxic granules that promote apoptosis of the infected cell. In 
this way, spreading of the infection to adjacent cells can be prevented 3.  
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ALLERGIC AIRWAY INFLA MMATION 
Allergic diseases, such as allergic rhinitis, are mediated via both the innate and the 
adaptive immune system, which initiate complex inflammatory responses against 
otherwise harmless environmental antigens like allergens. The clinical 
manifestations of allergic disorders can vary depending on how the allergen is 
introduced to the body, i.e. aeroallergens can cause nasal and ocular symptoms and 
they are often associated with asthma.  
 
ALLERGIC I MM UNE  RES PO NSES 
Many inflammatory cells and mediators are involved in the allergic process but the 
exact mechanisms behind this are still under investigation. However, the allergic 
inflammatory response can be divided in two main stages; the sensitization phase 
and the elicitation phase. In atopic individuals, initial exposure to allergen promotes 
activation of allergen-specific Th2 cells that secrete cytokines (e.g. IL-4 and IL-13), 
which in turn induce IgE production by B lymphocytes. Secreted IgE then binds to 
the surfaces of mast cells and basophils, in a process known as sensitization. The 
elicitation phase takes place upon re-encounter of the allergen. Then the IgE 
receptors on basophils and mast cells become cross-linked, which leads to 
degranulation and release of inflammatory mediators including cytokines and 
histamine. These mediators are responsible for early and late allergic responses. The 
former promotes the characteristic features of allergic rhinitis including nasal 
blockage (induced by vasodilatation and increased vascular permeability), 
rhinorrhea (by hypersecretion of water and mucus) and sneezing and itching 
(promoted by stimulation of afferent nerves).  
The latter is mediated via chemokines secreted from mast cells that recruit 
inflammatory cells, including eosinophils and Th2 cells, which contribute to tissue 
damage, sustained nasal blockage and wheezing in asthmatics 54-58. Some 
characteristic features of allergic inflammation are presented in F I G U R E  6.  
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F I G U R E  6 .  Some characteristic features of allergic inflammation. 
 
ALLERGIC RHI NITIS  
The incidence of allergic rhinitis has increased in most industrialized countries 
during the last 20 years. The reasons are still unclear but several different theories 
(including the hygiene hypothesis) have been put forward. However, the etiology of 
allergic rhinitis appears to be influenced by both genetic and environmental factors 
where tobacco smoke and respiratory pathogens have been suggested to dominate 
the latter 56. Clinically, allergic rhinitis is defined as a systematic disorder with nasal 
and ocular symptoms that include itching, sneezing, secretion and blockage upon 
allergen contact. It affects social life, sleep, school, work and quality of life 56, 59. 
Most patients with allergic rhinitis can be treated with pharmacotherapy, including 
antihistamines, intranasal corticosteroids and eye drops. However, for patients who 
have symptoms that are inadequately controlled by conventional pharmacotherapy, 
who cannot avoid the allergen, who suffer from adverse events of the allergy 
medications, or who wish to reduce the long-term use of medication, allergen-
specific immunotherapy is recommended as the first-line therapy 59-61.  
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ALLERGEN-S PE CIFIC I MM UNO TH ERA PY 
During allergen-specific immunotherapy, the dose of a specific allergen is gradually 
increased and administered to an allergic individual to induce tolerance. The 
treatment is indicated for patients with IgE-mediated allergic diseases that have 
been verified by i.e. history of allergic symptoms, positive skin prick test and 
presence of allergen-specific IgE in serum, and clinical symptoms 59, 62.  
Allergen-specific immunotherapy is the only treatment that affects the cause of the 
allergic disease and that has been shown to diminish allergic symptom, improve 
quality of life, prevent new sensitization and reduce development of asthma in 
allergic rhinitis patients 63-65. Currently, there are in principle four different routes 
for administration of allergen-specific immunotherapy; subcutaneous, sublingual, 
intralymphatic and epicutaneous.  
 
SUBCUT ANEOU S A LL ER G EN -SP EC I FIC I MM UNO T HER A PY 
The traditional route for administration of allergen-specific immunotherapy is 
subcutaneous injections and the efficacy of subcutaneous allergen-specific 
immunotherapy (SCIT) for treatment of respiratory disorders has been confirmed in 
numerous clinical studies 61, 62. However, only 5 % of allergic patients undergo SCIT 
and one reason for this is the long duration of the therapy 66, 67. The treatment 
protocol typically consists of an initiation phase where increasing amounts of 
allergen is injected weekly to the upper arm until a maintenance dose is reached, 
which thereafter is administered every 6-8 week for 3-5 years 62. Another 
disadvantage of SCIT is the risk of adverse events. For aeroallergens, up to 30% of 
the patients suffer from systemic reactions after allergen administration and 
redness, itch and edema in proximity to the injection site are often observed 62, 68. 
Although SCIT is considered the golden standard for allergen-specific 
immunotherapy, much effort has been put into finding more patient-friendly, non-
invasive and less time-consuming alternatives. 
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SU B L IN GU A L A LL ER GE N -SP EC I FI C I M MUNO TH E R A PY  
A more recent, non-invasive administration route is sublingual allergen-specific 
immunotherapy (SLIT), where the allergen extract is self-administrated in the form 
of tablets that are placed under the tongue once daily for approximately three years 
69, 70. Similar to SCIT, SLIT reduces allergic symptoms and provides long-term 
protective effects after discontinuation. In addition, the sublingual route has been 
associated with a better safety profile than SCIT since most adverse events are local 
and transient 69, 71-73. However, the duration of the treatment is the same as for SCIT 
and leaving the patient to self-medicate during such a long time can cause problems 
with compliance.  
 
EPI CUTAN E OUS A L LER G EN -SP EC I FIC I MM UNO T HER A PY  
In search of a needle-free, potentially self-administrable route for treatment of 
allergic disorders, the skin has gained increasing amount of interest. The skin has a 
high density of antigen-presenting cells and by applying allergen-containing patches 
to the epidermis, efficient antigen-delivery is ensured 74. Promising data, including 
reduced allergic symptoms during pollen season, have recently been presented for 
grass pollen allergy 75, 76. This treatment route has been described as convenient for 
the patients and although local eczematous skin reactions have be observed, EPIT 
appears to be safe and efficient 77. 
 
INTR A LY M PHA TIC AL L E R G E N-SP EC IF IC IM MU NO THER A P Y  
As immune responses are initiated within secondary lymphoid organs, direct 
intralymphatic injections of antigen emerged as a promising alternative when 
exploring novel potential administration routes for vaccines. 
During intralymphatic allergen-specific immunotherapy (ILIT), the allergen is 
injected into the inguinal lymph nodes under ultrasound guidance. Clinical trials 
have demonstrated that three intralymphatic injections with considerably lower 
allergen doses are able to induce tolerance and the treatment appears to be 
associated with fewer adverse events than SCIT. Clinically, ILIT with grass pollen 
extract has been demonstrated to ameliorate hay fever symptoms, to decrease skin 
prick test reactivity and to increase allergen tolerability. In addition, ILIT appears to 
reduce levels of allergen-specific IgE and induce IgG4 and IL-10 production 78. 
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MECH ANIS MS OF ALLE RGE N-S PE CIFI C  IMM UN OTHE RA PY 
The clinical effects and immunological mechanisms of allergen-specific 
immunotherapy are evaluated continuously 62. The treatment does not only affect 
clinical parameters (such as allergic symptoms during pollen season and upon 
allergen challenge, early and late allergic responses, quality of life and usage of 
allergy medications), but also several immunological parameters 79. The impact on 
cellular responses is particularly well-documented for SCIT and SLIT 80, 81.  
In the adaptive part of the immune system, allergen-specific immunotherapy has 
been shown to reduce activation of Th2 cells in favor for Th1 cells resulting in 
decreased IL-4 and IL-5 production and increased secretion of IFN-γ. It also 
promotes generation of IL-10-secreting regulatory T cells and decreases allergen-
specific proliferation. In addition, allergen-specific immunotherapy affects the 
production of antibodies from B cells. Initially, an increase in allergen-specific IgE 
levels can be observed, which is followed by a long-term decrease in favor for 
allergen-specific IgG4. 
Allergen-specific immunotherapy also affects the innate branch of the immune 
system. For example, successful treatment is associated with reduced recruitment 
of inflammatory cells (including eosinophils and mast cells) and prevented release of 
proinflammatory mediators 61, 67, 79, 81. An overview of some of the clinical and 
immunological effects of allergen-specific immunotherapy is presented in F I G U R E  
7.  Although SCIT, SLIT, ILIT and EPIT all appear to induce similar clinical effects, at 
least in a short perspective, the mechanisms of tolerance induction remains to be 
settled. 
 
 
F I G U R E  7 .  Overview of clinical and immunological changes induced by allergen-specific 
immunotherapy. 
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MATERIALS AND METHODS 
This section contains a brief overview of the materials and methods used in the 
thesis. For more detailed descriptions, the reader is referred to the individual 
articles (P A P E R S  I -V ).  
 
HUMAN STUDY POPULATIONS 
In all studies, fresh human materials were utilized.  
¾ In P A P E R  I , tonsils were acquired from 28 pediatric patients undergoing 
tonsillectomy due to tonsillar hyperplasia. Buffy coats were obtained from 21 
healthy donors. 
 
¾ P A P E R  I I  is based on tonsils from 28 pediatric patients undergoing 
tonsillectomy due to recurrent infections or tonsillar hyperplasia. 
 
¾ In P A P E R  II I , fresh peripheral blood and buffy coats were collected from 
allergics and healthy individuals. 
 
¾ In P A P E R  IV , peripheral blood was drawn and nasal lavage fluids were 
collected from 28 patients with allergic rhinitis before and after treatment with 
active or placebo ILIT.  
 
¾ In P A P E R  V , blood samples were acquired from 35 subjects with allergic 
rhinitis before and after treatment with active or placebo ILIT. 
 
METHODS 
This thesis can be divided into two partly integrated parts, the first (P A P E R S  I - II I ) 
focusing on the expression and function of PRRs in subsets of leukocytes (B 
lymphocytes, T lymphocytes and eosinophils, respectively), and the second 
(P A P E R S  IV -V ) evaluating the clinical and cellular effects of ILIT. 
All studies were performed at Skåne University Hospital Malmö after approval from 
the Ethics committee of Lund University and/or Karolinska Institutet. Written 
informed consent was obtained from all participants or the parents of pediatric 
subjects.  
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PART I .  
In P A P E R S  I - I II , mononuclear cells or granulocytes were isolated from tonsils 
and/or peripheral blood by density gradient centrifugation. Occasionally, the 
separation was followed by negative selection using antibody-conjugated magnetic 
beads. Isolated cells were analyzed for mRNA and protein expression using real-time 
reverse transcription (RT)-polymerase chain reaction (PCR), immunohistochemistry 
and flow cytometry. Cells were also used in various in vitro studies after culture in 
absence or presence of specific PRR ligands. Expression of cell surface and activation 
markers (flow cytometry), cytokine release (enzyme-linked immunosorbent assay; 
ELISA), viability and apoptosis (flow cytometry), and proliferation ([methyl-
3H]Thymidine incorporation) were assessed as depictured in F I G U R E  8 . 
 
 
F I G U R E  8 .  Schematic overview of the methods used in papers I-III. 
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CEL L I S OLA TI ON  
Ficoll-PaqueTM, can be used to separate cells of different density. Granulocytes and 
erythrocytes with high density quickly sediment to the bottom of the tube, whereas 
mononuclear cells (including lymphocytes and monocytes) with light density are 
found in the interface of plasma (above) and Ficoll-PaqueTM (below).  
The gradient centrifugation was occasionally followed by magnetic separation to 
obtain highly purified cell populations (such as B lymphocytes, T lymphocytes and 
eosinophils). Then, freshly isolated cells were incubated with a cocktail of primary 
antibodies directed towards unwanted cells (such as NK cells, macrophages, 
monocytes) followed by antibody-conjugated antibodies against the primary 
antibodies. Finally, the cell suspension was passed through a magnetic column and 
stained cells were retained in the column, whereas unlabelled cells (CD19+ B cells in 
P A P E R  I , CD3+ T cells in P A P E R  I I  and CD16- eosinophils in P A P E R  I II ) passed 
through.  
 
REA L-T IM E RT-PCR 
Real-time PCR enables quantification of gene expression. The procedure begins with 
extraction of total RNA from isolated cells followed by reverse transcription of RNA 
into complementary DNA (cDNA). During the quantification process, cyclic heating 
and cooling denatures the double-stranded cDNA, enables attachment of sequence-
specific DNA probes and promotes annealing/extension of new DNA strands.  During 
amplification, the quencher fluorophore of the probe is separated from the reporter 
fluorophore, giving rise to measureable fluorescence. When the emitted 
fluorescence reaches a predetermined value, a cycle threshold (Ct) value can be 
determined. Using the comparative Ct method, the obtained Ct value of the 
investigated gene is subtracted with the value for the housekeeping gene (β-actin) 
and in this thesis, the amount of mRNA is presented in relation to 100,000 
molecules of β-actin as 100,000 x 2-ΔCt 12, 13.  
In all three papers, RNA was extracted from isolated cells using the RNeasy mini kit 
(Qiagen) and the RNA quality and concentration was estimated based on the 
wavelength absorption ratio (260/280 nm) determined by spectrophotometry. 
During the second step, RNA was reversibly transcribed into cDNA using Omniscript 
reverse transcriptase kit (Qiagen) with oligo-dT primer. 
Quantitative PCR was performed either on a Smart cycler II (Cepheid, P A P E R  I ) or a 
Stratagene Mx3000 (Agilent Technology, P A P E R S  I I - II I ) using FAM-labelled 
probes from Applied Biosystems and Taqman® Universal PCR Mastermix, No 
AmpErase UNG and Assay on-Demand gene expression products (Applied 
Biosystems) or Stratagene Brilliant® QPCR Mastermix (Agilent technology), 
respectively.  
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IM MUN OH I STO CH E MI ST R Y  
Immunohistochemistry can be used for detection of various proteins in tissues and 
cells. The method is based on visualization of specific antigens using primary 
antibodies that subsequently are detected with enzyme-labelled polymers 
conjugated to secondary antibodies. After incubation with a substrate (for example 
3,3-diaminobenzidine (DAB) or Fast Red), positive immunoreactivity can be 
identified as brown or red precipitates, respectively. To give contrast to the sections 
and to visualize nuclei, counterstaining with haematoxylin was performed and slides 
were examined using bright field microscopy. To rule out unspecific background 
staining, universal negative control for mouse or rabbit primary antibodies and 
antibody diluents were used.  
Immunohistochemistry was applied for detection of NLR and RLR proteins. In 
P A P E R S  I - I I , paraffin-embedded tonsillar tissues were used. To identify the 
locations of B and T lymphocytes within the tissues, primary antibodies against CD3 
and CD20 were utilized. CD20+ B cells were primarily detected within the germinal 
centers, whereas CD3+ T cells were found in the adjacent areas. In P A P E R S  I - II I , 
highly purified B cells, T cells and eosinophils were assessed for NLR and RLR protein 
expression.  
 
FLOW CY TO M ETRY  
Flow cytometry can simultaneously measure multiple physical and chemical 
properties of individual cells based on how they scatter incident light from a laser 
beam. Using different detectors, the flow cytometer provides information about cell 
size (displayed by forward scatter; FSc), granularity (displayed by side scatter; SSc) 
and fluorescence intensity of fluorochrome-conjugated antibodies used for 
detection of intra- or extracellular antigens. By gating on FSc and SSc, lymphocytes, 
monocytes and granulocytes can easily be distinguished. In the present thesis, 
analyses were performed on Epics XL or FC500 flow cytometer from Beckman 
Coulter and data were analyzed using Expo32 ADC software or CxP Analysis 
software (Beckman coulter). 
In P A P E R S  I - I I  A N D  IV ,  B and T lymphocytes were identified as CD19+ and 
CD3/CD4/CD8+ lymphocytes and monocytes as CD14+ cells, and in P A P E R S  I I I  A N D  
V ,  eosinophils and neutrophils were discriminated as CD16- or CD16+ granulocytes, 
respectively (F I G U R E  9 ).  
Flow cytometry was used for determination of intracellular protein expression of 
various members of the NLR and RLR families (P A P E R S  I - II I ) and regulation of 
extracellular activation markers (P A P E R S  I -V ). In P A P E R S  I  A N D  I I I ,  the viability 
of stimulated cells was determined using staining with Annexin V (ANX-V) and 
propidium iodide (PI). The former binds to phosphatidylserine that is translocated to 
the plasma membrane during apoptosis, whereas the latter is a nucleic acid dye that 
can be used to discriminate between dead and apoptotic cells, respectively 82.  
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F I G U R E  9 .  Flow cytometric identification of cell population based on FSc and SSc properties. 
 
ELISA 
ELISA is a sensitive method for detection and quantification of antigens and/or 
antibodies present in for instance serum, cell culture supernatants and nasal lavage 
fluids. In this thesis, the ELISAs used are of so-called “sandwich” type. In short, a 
capture antibody directed towards the antigen of interest is coated to a microplate. 
When standards (with known concentration) or samples are applied, the antigen 
binds to the immobilized antibody and thereafter an antigen-specific enzyme-linked 
polyclonal antibody is added for detection. Lastly, a substrate initiates color 
development that is proportional to the amount of antigen in the sample. 
In P A P E R  I I ,  commercial ELISA kits from RnD systems were used to determine 
levels of IL-2, IL-4, IL-10 and IFN-γ in supernatants. In P A P E R  II I , cell culture 
supernatants were assessed for IL-8 and RANTES using plates from RnD systems and 
levels of EDN and IFN-α using kits from MBL and PBL Biomedical laboratories, 
respectively. In P A P E R  IV , levels of IL-8 in nasal lavage fluids and IL-10 secretion 
were measured with ELISA plates from RnD systems.  
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[MET HYL- 3H]TH Y MI DI NE I NCOR POR A TI ON 
The [methyl-3H]Thymidine incorporation assay is a method used for quantification 
of proliferation. It is based on measurements of incorporated levels of radio labelled 
Thymidine during mitotic cell division. After cell culture in the presence of tritiated 
Thymidine, cells are harvested onto glass fiber filter discs and the extent of cell 
divisions is determined by a scintillation beta-counter based on the levels of 
radioactivity in the DNA recovered from the cells. 
In P A P E R  I , proliferative responses to NLR and TLR ligands in purified tonsillar and 
peripheral B cells were determined. In P A P E R  I I ,  Thymidine incorporation was 
measured in cultured CD3+ tonsillar T cells and tonsillar mononuclear cells, and in 
P A P E R  IV  allergen-specific proliferation of peripheral blood mononuclear cells was 
assessed.  
 
PART II.   
P A P E R S  IV  A N D  V  are based on a pilot study followed by a double-blind placebo-
controlled clinical trial of intralymphatic administration of allergen-specific 
immunotherapy as treatment for pollen-induced allergic rhinitis (F I G U R E  1 0 ).  
Leukocyte numbers and distribution, levels of total and specific serum-Igs as well as 
various cell surface markers were analyzed in whole blood. Nasal allergen 
provocations with symptom scoring were performed and nasal lavage fluids were 
collected and analyzed for inflammatory cells and mediators. 
All study subjects were treated with three intralymphatic 0.1 ml injections of either 
placebo (allergen diluent, ALK Abéllo) or 10,000 SQ-U/ml of a standardized, 
aluminum hydroxide-adsorbed, depot birch- or grass-pollen vaccine (Alutard®, ALK 
Abéllo). The injections were given with an interval of approximately four weeks. 
 
 
F I G U R E  1 0 .  Study outline of papers IV and V. 
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SUBJ E CT CH ARACT ER IZ AT I ON  
In P A P E R S  IV  A N D  V ,  recruited patients exhibited moderate to severe 
birch/grass-pollen induced rhinoconjunctivitis with symptoms including itchy nose 
and eyes, sneezing, nasal congestion and secretion. Allergy was verified by a 
positive skin prick test, presence of allergen-specific IgE in serum and a positive 
nasal provocation test 62. General contraindications were pregnancy or nursing, wish 
for pregnancy, autoimmune and collagen disease, cardiovascular disease, current 
persistent asthma, upper airway disease (non-allergic sinusitis, nasal polyposis), 
chronic obstructive and restrictive lung disease, hepatic and renal disease, cancer, 
previous immuno- or chemotherapy, major metabolic disease, alcohol or drug 
abuse, mental incapability of coping with the study or medication with a possible 
side-effect of interfering with the immune response. 
 
SKI N PR I CK T E ST  
Skin prick tests were performed using a standard panel of 11 common airborne 
allergens (ALK Abéllo) including pollen (birch, timothy, mug worth and ragweed), 
house dust mite (D. pteronyssinus and D. farinae), molds (Cladosporium and 
Alternaria) and animal allergens (cat, dog, horse). Testing was performed on the 
volar side of the forearm with saline buffer as negative control and histamine 
chloride (10 mg/ml) as positive control. All included patients presented a wheal 
reaction diameter of more than 3 mm towards birch or grass after 15 min. 
 
BLO OD T ES TI NG  
Blood was obtained from participants at baseline, after completion of treatment, 
and at the end of the pollen season following end of treatment. Levels of serum 
allergen-specific IgE and IgG4 were determined using the Phadia CAP system and 
total and differential leukocyte counts were determined in a Counter LH750/GenS 
cell counter (Beckman Coulter). 
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NA SA L AL L ER G EN C HA L LE NG E W IT H S Y MPT O M SC O R IN G 
Purified birch or grass allergen extracts (10,000 SQ-U) were delivered in each nasal 
cavity by a mechanical pump 83, 84. Subjects were asked to record the occurrence 
and severity of allergic symptoms (including nasal itch, secretion and congestion) 
using a scale from 0 to 3 (0= no symptoms, 1= mild symptoms, 2= moderate 
symptoms and 3= severe symptoms) before and after (5, 15 and 30 min after) the 
provocation 85. 
In P A P E R  IV ,  study subjects were intranasally challenged before and 4 weeks after 
ILIT to confirm seasonal allergic rhinitis and to monitor the treatment outcome. In 
P A P E R  V ,  nasal provocation tests were performed before and 4 weeks after the 
treatment as well as at the end of the following pollen season. 
 
NA SA L LAV A G E AND CE L L  COU NT S 
Collection of nasal lavage fluids is a non-invasive method used for studying the 
inflammatory responses of the nose. In P A P E R  IV ,  a sterile saline solution was 
alternately aerosolized into the nostrils after clearing of excess mucus. The nasal 
fluids were passively collected in a test tube until 7 ml was recovered 83, 84, 86. The 
derived fluids mainly contain inflammatory mediators and cells (leukocytes and 
epithelial cells) 87. The numbers of cells were counted in a Bürker chamber and the 
fluids were thereafter centrifuged, separated from the cells and stored at -70°C until 
analysis. The IL-8 levels in the collected nasal lavage fluids were analyzed with ELISA.  
 
QUESTI ONN AIR E S  
In P A P E R S  IV  A N D  V , the trial staff recorded the occurrence of local and systemic 
reactions during the first hour after every intralymphatic injection. Late reactions 
during the next 24 hours were self-registered by the patients. The study subjects 
were also asked to estimate the discomfort associated with the injection using an 
arbitrary scale ranging from 0-10 (0- completely painless and 10- worst experienced 
pain) and relate it to the discomfort of a venous puncture (more painful, the same 
pain, less painful, no pain at all).  
At the end of the first allergy season after the finished treatment, study subjects 
were asked to compare their allergic symptoms during the recent pollen season 
with the symptoms they experienced the season just before treatment. For this, a 
visual analog scale (VAS) ranging from 0 (unchanged symptoms, no improvement) to 
10 (total symptom relief, complete recovery) was used. In addition, patients 
recorded if their total use of allergy medication (including oral histamines, intranasal 
corticosteroids, eye drops, inhaled β2-agonists and systemic corticosteroids) 
changed during the pollen season as a result of the treatment. 
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STATIS TI CAL  AN ALYSE S  
Statistical analyses were performed using Graphpad Prism. In P A P E R S  I - I II ,  data 
are presented as mean ± standard error of the mean (SEM) and in P A P E R S  IV -V  as 
mean ± SEM or individual values in combination with a horizontal line representing 
the mean value. A p-value of 0.05 or less was considered statistically significant and 
n equals the number of performed experiments or included subjects. 
Distribution of data was assessed using D’Agostino and Pearson omnibus normality 
test. Normally distributed data were analyzed using parametric tests and data not 
normally distributed by non-parametric tests. 
For comparison of two data sets, paired or unpaired t-tests were employed for 
parametric data, whereas Wilcoxon’s signed rank tests or Mann-Whitney tests were 
used for non-parametric data. For more than two paired data sets, one-way 
repeated measures ANOVA along with Dunnett’s or Bonferroni post-test were 
utilized. 
Nonrandom associations between two categorical variables were determined by 
Fisher exact test. 
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NOD-LIKE AND RIG-LIKE RECEPTORS IN 
HUMAN LEUKOCYTES 
 
RESULTS PAPERS I-III 
NLRs and RLRs are recently discovered cytosolic PRRs that detect conserved 
microbial structures and trigger innate immunity. Their expression has been 
reported in several different cell types, but studies regarding their presence in the 
human system are limited. Information about their functional activities is even more 
restricted as synthetic ligands only are available for NOD1 (iE-DAP), NOD2 (MDP), 
NALP3 (aluminum hydroxide) and RIG-I/MDA-5 (poly(I:C)/LyoVec). In the first part of 
the thesis, the aim was to characterize expression and functional activities of NLRs 
and RLRs in subsets of human leukocytes. 
At mRNA level, a range of NLRs and RLRs, including NOD1, NOD2, NALP3, RIG-I and 
MDA-5, was found in B lymphocytes, T lymphocytes and eosinophils (F I G U R E  1 1 ). 
When tonsillar and peripheral cells were compared, a differential expression was 
found. In general, blood-derived B cells exhibited higher levels of the receptors than 
lymphoid cells. However, no differences were seen among naïve, germinal center or 
memory B cells and neither between Th1 nor Th2 tonsillar cells. Unpublished data 
from our department show that patients suffering from allergic rhinitis exhibit the 
same expression levels of NOD-like and RIG-like receptors as healthy individuals 
without allergy.  
 
F I G U R E  1 1 .  mRNA expression of selected NOD-like and RIG-like receptors in human B cells, 
T cells and eosinophils was determined using real-time RT-PCR. Data are presented in relation 
to the internal control gene E-actin as 2-'Ct u 105 and depicted as mean ± SEM.  
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Protein expression of the receptors was confirmed using immunohistochemistry 
(F I G U R E  1 2 ) and flow cytometry. Staining of tonsillar tissue sections revealed 
presence of NLRs and RLRs both in the germinal centers were B cells reside, and in 
the adjacent T cell areas. Corresponding proteins were found in purified B and T 
lymphocytes. Immunostaining of eosinophils showed expression of NOD1 and 
NOD2, low levels of RIG-I and MDA-5, whereas NALP3 protein was completely 
absent.  
 
 
F I G U R E  1 2 .  Protein expression of NOD1, NOD2, NALP3, RIG-I and MDA-5 in tonsillar tissue 
and purified eosinophils was confirmed using immunohistochemistry. Slides were 
counterstained with haematoxylin and analyzed by microscopy. 
 
To study the functional relevance of NLRs and RLRs, purified cells were cultured in 
the absence or presence of agonists specific for the receptors. However, due to the 
ongoing debate regarding the specificity of Alum and poly(I:C)/LyoVec along with 
the low protein levels of NALP3 and RIG-I/MDA-5 observed, only the functional 
responses of NOD1 and NOD2 will be presented. 
In lymphocytes, none of the ligands were able to induce activation without 
concomitant signals via the BCR or the TCR, respectively. However, upon stimulation 
via IgM/IgD or CD3/CD28, an activated B and T cell phenotype was observed as 
manifested by induced proliferation (FI G U R E  1 3 ), enhanced viability, up-regulated 
expression of cell surface markers and increased cytokine secretion. Co-stimulation 
via CD40L (to mimic the interaction with T cells) failed to induce further B cell 
activation. The functional responses were generally higher in B cells obtained from 
blood than tonsillar tissues, which is well in line with the expression profile.  
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F I G U R E  1 3 .  Proliferation of tonsillar B and T lymphocytes was determined using [methyl-
3H]Thymidine incorporation. Data are presented as mean ± SEM. * p0.05, *** p0.001. 
 
Although all PRRs are involved in the defense against invading pathogens, their 
cellular locations vary. The NLRs and the RLRs are located in the cytosol, whereas 
the TLRs are found on the cell surface or within the endosomes. Emerging evidence 
suggest that the receptor families cooperate to ensure effective detection and 
clearance of infections. To investigate if such an interaction applies also in B 
lymphocytes, purified cells were stimulated with iE-DAP or MDP in combination 
with agonists for TLR1/2 (Pam3CSK4), TLR7 (R-837) or TLR9 (CpG) in the absence or 
presence of BCR triggering. Results revealed that the NLR and the TLR systems could 
cooperate to potentiate proliferation (F I G U R E  1 4 ). 
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F I G U R E  1 4 .  Cooperative effects of the NOD1 ligand and TLR agonists on proliferative 
responses of tonsillar and peripheral B cells was determined using [methyl-3H]Thymidine 
incorporation. Data are presented as mean ± SEM. * p0.05. 
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Unlike lymphocytes that constitute the cellular elements of the acquired immunity, 
eosinophils are part of the innate immune system. They are involved in the 
elimination of parasitic infections, but a growing body of evidence suggests that 
they also have a function in the recognition and killing of bacteria and viruses. 
Respiratory infections induced by these pathogens are known to promote 
hyperreactive responses, but the mechanisms behind such microbe-induced 
exacerbations are still far from understood. One possible explanation could be an 
activation via the PRR system. 
Both the NOD1 and NOD2 ligands were able to activate purified eosinophils, as 
displayed by changed levels of the activation markers CD11b, CD62L and CD69, 
induced secretion of IL-8 and enhanced chemotactic migration (F I G U R E  1 5 ). This 
is in agreement with the observed mRNA and protein expression.  
 
 
F I G U R E  1 5 .   IL-8 secretion, regulation of CD11b and chemotactic migration of eosinophils 
was assessed using ELISA, flow cytometry and a migration assay, respectively. Data are 
presented as mean ± SEM. * p0.05, ** p0.01, *** p0.001. 
 
To evaluate possible involvement of these receptors in microbe-induced 
exacerbations of allergic airway inflammation, eosinophils were also stimulated with 
NOD agonists in the absence and presence of Th1- and Th2-like cytokines. In the 
presence of cytokines regulating Th2 immunity (IL-5 and GM-CSF), the NLR induced 
activation was augmented, which was evidenced by increased levels of 
inflammatory mediators (F I G U R E  1 6 ). 
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F I G U R E  1 6 .  After priming of NOD1 and NOD2 responses using IL-5, GM-CSF and IFN-γ, 
secretion of IL-8 by eosinophils was determined using ELISA. Data are presented as mean ± 
SEM. * p0.05, ** p0.01, *** p<0.001. 
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COMMENTS PAPER S I-III 
In the first part of the thesis, the presence of a range of NLRs and RLRs is 
demonstrated in human primary leukocytes. We also provide evidence for their 
importance in the recognition and clearance of bacterial infections and suggest a 
role for these receptors as a link between respiratory infections and exacerbations 
of allergic diseases.  
Although PRRs belong to the innate branch of the immune system, we amongst 
others have previously demonstrated an active role of Toll-like receptors in 
lymphocytes 12, 13. Encouraged by these observations, presence of the related NOD-
like and RIG-like receptors was assessed in B and T lymphocytes. Lymphocytes were 
found to exhibit a range of NLRs and RLRs and differences in expression profiles and 
functional activities were observed between blood-derived and tonsillar cells. 
However, the evaluation of functionalities was limited since ligands are only 
available for NOD1 (iE-DAP), NOD2 (MDP), NALP3 (aluminum hydroxide) and RIG-
I/MDA-5 (poly(I:C)/LyoVec). Also, it is worth mentioning that there is an ongoing 
discussion regarding the specificities of some of these agonists.  
The NOD proteins are involved in the recognition of peptidoglycans where NOD1, 
specifically respond to iE-DAP and NOD2 to the L-D isomer of MDP. In agreement, 
both lymphocytes and eosinophils were activated by these agonists while being 
completely unresponsive to the control compounds D-glutamyl-lysine (iE-Lys) and 
the D isomer of MDP. In contrast, NALP3 is known to respond to microbial products 
and host-derived danger signals. There are recent studies demonstrating a role for 
the NALP3 inflammasome in the recognition of the adjuvant Alum, but it seems to 
be unclear whether this interaction is NALP3-specific.  
RIG-I and MDA-5 take part in the recognition of intracellular viruses and these 
receptors can, according to the manufacturer, be activated by the synthetic ligand 
poly(I:C)/LyoVec. However, this ligand consists of poly(I:C)s complexed to the 
transfection agent LyoVecTM allowing intracellular delivery. Therefore, its effects via 
endosomal TLR3 cannot be completely ruled out.  
The different responses of tonsillar and peripheral B cells might be related to 
divergent cellular compositions of the two compartments and also to variations in 
the antigenic load. There is a larger proportion of resting B cells in the periphery 
than in lymphoid tissues and obviously blood lacks germinal center B cells 88. Also, 
tonsillar lymphocytes are constantly exposed to pathogens, which might affect the 
receptor expression. In contrast to studies on TLRs showing that the differentiation 
process and microbial infections influence the expression profiles 13, 89-92, the NLR 
levels were unaffected by both the differentiation stage of the B cell and ongoing 
tonsillar infections.  
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The onset of adaptive immunity is traditionally believed to be dependent on the 
recognition of pathogens by innate immune cells expressing PRRs. Over the last 
decades, this view has been modified as an increasing number of studies have 
demonstrated that various PAMPs (such the TLR9 ligand CpG) can directly activate B 
cells even in the absence of co-stimulatory signals 13. In contrast to some TLR 
ligands, stimulation with the NOD1 and NOD2 agonists alone is not sufficient to 
induce lymphocyte activation. However, when the lymphocytes are provided with 
the first activation signal (via the BCR/TCR), the cells are able to respond 
unspecifically to certain microbial components via their PRRs. Therefore, it seems 
reasonable to update the traditional “two-signal model” of lymphocyte activation to 
include signals provided via the PRR system. 
Emerging numbers of studies have demonstrated a close interaction between 
different members of the PRR families. In agreement, we demonstrate cooperative 
effects of NLRs and TLRs in B lymphocytes. During bacterial infections, invading 
pathogens most probably engage several different PRRs simultaneously. It has been 
proposed that the cytosolic PRRs function as a backup system for the recognition of 
bacteria and viruses having escaped the initial detection via cell surface TLRs or 
released from the endosomal compartments. The cooperation between these 
receptor families might provide the immune system with a valuable defense 
mechanism ensuring effective detection and clearance of invading pathogens.  
Although the PRRs are supposed to protect the host from infections, these 
receptors have been increasingly implicated in various human disorders 33, 34. During 
the last decades, the prevalence of allergic disorders has increased 59. This might be 
related to the so-called hygiene hypothesis that suggests that a reduced microbial 
exposure during childhood is linked to increased susceptibility to develop allergic 
diseases. A well-known example of this is the exposure to LPS (recognized via TLR4) 
in farmer’s children, who appear to be protected against allergy development 35, 36. 
For the related NLRs, such a link is under investigation but polymorphisms in the 
NOD1 and NOD2 genes have already been associated with allergic disorders, asthma 
and atopy-related traits 37-40. In addition, our group has shown that patients 
suffering from symptomatic allergic rhinitis exhibit lower levels of NOD1 and NALP3 
than healthy controls and allergics outside pollen season 93. However, in 
lymphocytes (unpublished observations) and eosinophils obtained from healthy 
individuals and allergic subjects, no differences in NLR expression or activation 
profiles have been observed. 
Eosinophils are important in early innate immune responses, but they also have a 
role in allergic disorders affecting inflammation, hyperresponsiveness and 
remodeling of the airways 41, 43, 94. In the allergic airways, bacteria and viruses can be 
as potent as allergens in promoting hyperreactive responses and aggravating 
allergic symptoms 95-97. The mechanisms behind these microbe-induced 
exacerbations are still far from understood, but one explanation could be an 
activation of eosinophils through their PRRs. We demonstrate that eosinophils can 
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be activated via the NLR system and that the responses are augmented in the 
presence of Th2-promoting cytokines. This is in agreement with a previous study 
from our laboratory that shows TLR-induced responses of eosinophils to be 
enhanced upon pre-treatment with IL-5 and that patients with allergic rhinitis 
respond more strongly to TLR-stimulation than healthy individuals 98, 99. Together, 
these results make it tempting to speculate that these receptors constitute a 
pathway linking allergic exacerbations with respiratory infections. However, the 
responses induced by the NLR agonists alone are of a fairly low magnitude, 
especially as compared to stimulation with whole bacteria. Nonetheless, these 
receptors may function as fine-tuners in the mounting of appropriate immune 
responses. In a biological system, it is most likely the combined actions of several 
receptors and mediators that are of importance and not the effects exerted by the 
individual receptors alone. 
In conclusion, the first part of this thesis demonstrates functional NLRs and RLRs in 
both lymphocytes and eosinophils. The active role of PRRs in cells traditionally 
belonging to the adaptive immune response emphasizes the important cross-talk 
between the two branches of the immune system. In addition, we show that PRR-
induced eosinophil responses can be enhanced in the presence of cytokines 
associated with an allergic phenotype. This together with the knowledge that 
eosinophils are accumulated in hyperreactive airways further highlight the possible 
role of PRRs not only in virus-induced but also in bacteria-induced exacerbations of 
allergic respiratory diseases. 
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INTRALYMPHATIC ALLERGEN-SPECIFIC 
IMMUNOTHERAPY 
 
RESULTS PAPERS IV-V 
Allergen-specific immunotherapy can be used to treat patients with allergic rhinitis 
and asthma. The clinical improvement following treatment is extensively 
documented but despite its proven efficacy, only a minority of all patients eligible 
for treatment undergoes therapy. One reason for this is the long treatment duration 
of conventional SCIT. However, as immune responses are initiated within secondary 
lymphoid organs, intralymphatic allergen administration has recently emerged as a 
less time-consuming alternative to conventional treatment. In the second part of 
the thesis, the aim was to evaluate ILIT for treatment of pollen-induced allergic 
rhinitis.  
Using ultrasound guidance, the superficial inguinal lymph nodes were identified as 
hypoechoic nodules (F I G U R E  1 7 ), and 1,000 SQ-U of allergen extract was slowly 
injected. The patients reported that the injections were virtually painless and not 
associated with greater discomfort than a venous puncture. Treatment-induced 
reactions were in most cases restricted to minor swelling, redness and itch in 
conjunction to the injection site. No severe adverse events were reported. However, 
it is worth mentioning that one patient who was not included in the initial studies (a 
placebo patient from the first study that later was given active treatment), reported 
local redness and swelling in a somewhat greater area around the injection site as a 
result of the first allergen injection. This reaction was recorded during the first 30 
min period after the injection and it was resolved within an hour. 
 
 
F I G U R E  1 7 .  Ultrasound image of an inguinal lymph node. 
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Actively treated patients showed improved symptoms upon allergen challenge 
along with a decreased inflammatory response in the nose as manifested by 
reduced numbers of inflammatory cells and IL-8 levels in nasal lavage fluids 
(F I G U R E  1 8 ). Additionally, the clinical improvements were accompanied with 
increased levels of allergen-specific IgE, whereas no significant effects were seen in 
allergen-specific IgG4 levels.  
 
 
F I G U R E  1 8 .  Changes of clinical parameters after treatment with intralymphatic allergen-
specific immunotherapy. Data are presented as mean ± SEM. * p0.05. 
 
Patients receiving active treatment also reported an improvement of their seasonal 
symptoms (F I G U R E  1 9 ) and a reduction in their use of allergy medication.  
 
 
F I G U R E  1 9 .  Patient-recorded treatment outcome. The study subjects were asked to rank 
the change in their allergic symptoms as compared to the pollen season preceding 
intralymphatic treatment. * p0.05. 
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After the evaluation of the safety and the clinical effects of ILIT, the next step was to 
identify cellular and molecular changes mediated by the treatment. Among the 
actively treated patients, ILIT promoted both short-term and long-term activation of 
neutrophils and eosinophils as shown by an up-regulated expression of cell surface 
markers (F I G U R E  2 0 ).  
 
 
F I G U R E  2 0 .  Activation of granulocytes after intralymphatic allergen-specific 
immunotherapy. Data are presented as mean ± SEM. * p0.05, ** p0.01. 
 
In contrast to the enhanced activation seen among granulocytes, a reduced 
percentage and activation of Th2 cells were observed along with fewer regulatory T 
cells (F I G U R E  21 ). 
  
46. 
 
 
F I G U R E  2 1 .  Activation of lymphocytes after intralymphatic allergen-specific 
immunotherapy. Data are presented as mean ± SEM. * p0.05, ** p0.01. 
 
As can be seen in F I G U R E  19 , the actively treated patients can be divided in two 
subgroups, one consisting of 12 patients reporting a clear improvement of their 
seasonal symptoms and another subgroup of 8 patients that did not experience any 
relief. The former group also exhibited a marked reduction of reported symptoms in 
response to the nasal allergen challenge, whereas the latter described no such 
change (F I G U R E  2 2 ). The patients in the improved actively treated subgroup 
reported that they were able to reduce their intake of allergy medication during 
pollen season.  
 
F I G U R E  2 2 .  Allergic symptoms upon allergen provocation among improved subjects, non-
improved patients and placebo controls. Data are presented as mean ± SEM. * p0.05, ** 
p0.01.   
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COMMENTS PAPER S IV-V  
The potency of intralymphatic administration of vaccines has been studied in 
various models 78, 100-103 and the first reported use of ILIT for treatment of allergic 
rhinitis in humans by Senti and colleagues 78 attracted the attention of many 
allergologists as the intralymphatic route appeared to be an efficient alternative to 
conventional SCIT. In the second part of the thesis, we have evaluated the effects of 
ILIT for treatment of birch- or grass-pollen induced allergic rhinitis. We demonstrate 
that ILIT is safe for the patient, reduces allergic symptoms upon nasal allergen 
challenge and during pollen season, decreases the inflammatory response of the 
nose and affects the activation profiles of peripheral lymphocytes and granulocytes. 
We have used the same approach as Senti and colleagues and administered three 
intralymphatic injections of 1,000 SQ-U of allergen with 4 weeks intervals 78 as this 
time interval has been proven to be sufficient to allow formation of antigen-specific 
B cell responses and for affinity maturation of memory B cells 104, 105. The allergen 
injected in the present investigation is the same as we use for regular SCIT 
treatment, but the administered dose is about 100 times lower. For SCIT the 
maintenance dose is 100,000 SQ-U and it has been reported that up to 30% of 
patients treated with conventional SCIT suffer from systemic reactions after allergen 
administration 68. The ILIT dose of 1,000 SQ-U might be one explanation for the 
good safety profile seen with this administration route. Only one of our patients 
(who was not part of the initial study) suffered from a moderate local reaction and 
otherwise the treatment-induced adverse events were restricted to redness, itch 
and swelling in close proximity to the injection site. 
In the inguinal regions, the lymph nodes are often found just a few millimeters 
under the skin surface and they can easily be detected using ultrasound. The sparse 
sensory innervation of these nodes can explain the lack of discomfort during and 
after the injections 106. Although intralymphatic injections can be administered 
within minutes by skilled physicians, there are some technical aspects that need to 
be considered. Once the lymph nodes have been identified, 0.1 ml allergen should 
be injected into a lymph node with an average size of 0.5-1.0 cm. In addition to the 
requirement of ultrasound equipment, the procedure necessitates simultaneous 
work with both hands, holding the probe in one and injecting the allergen with the 
other. Even when using a fine needle for administration, it can be difficult to 
penetrate the capsule surrounding the lymph node. This could lead to inadequate 
administration of the allergen near instead of in the lymph node. There is also a risk 
for allergen “leak out” when the needle is removed. These factors might limit the 
broad use of this treatment route at the allergy clinics. 
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Reported clinical effects of SCIT include e.g. improved quality of life, diminished 
seasonal allergic symptoms and medication use as well as reduced skin prick test 
reactivity 63-65. In our studies, we demonstrate that patients receiving active ILIT 
experience improvement of their seasonal allergic symptoms in combination with 
decreased nasal symptoms upon allergen challenge. In addition, there seems to be a 
reduction in the nasal inflammatory response which might reflect a skewing 
towards a more non-allergic, non-inflammatory cytokine profile. 
It is tempting to speculate that ILIT and SCIT might share some humoral and cellular 
hallmarks. It is well-known that SCIT can promote an initial increase of allergen-
specific IgE followed by a long-term decline in favor for IgG4 60, 107, 108. For ILIT, an 
induction of allergen-specific serum IgE was observed, whereas no effects on IgG4 
production were found. On a cellular level, SCIT reduces the activation of Th2 cells 
in favor of Th1 responses and induces activation of regulatory T cells 61, 64, 65, 109.  
Regarding the effects on peripheral innate immune responses, little information is 
available. Among actively treated patients, ILIT was shown to promote continuous 
activation of granulocytes, which most likely is due to the retention of alum at the 
injection site. Although this continuous stimulation might cause a local chronic 
inflammation, it appears as if this innate immune activation is required for tolerance 
induction.  
In the adaptive part of the immune system, ILIT promoted an initial activation of Th 
cells followed by reduced activation of Th2 lymphocytes and regulatory T cells. 
Although ILIT appears to share some markers of SCIT, some defining features seem 
to differ. However, it is possible that the altered administration route induces at 
least partly different mechanisms without interfering with the clinical outcome. 
Further studies will be needed to identify which treatment-induced changes that 
induce beneficial effects and which events that are merely a marker for such effects.  
In summary, the second part of this thesis demonstrates that ILIT constitutes a safe 
and effective treatment strategy for pollen-induced allergic rhinitis. From an 
economical, societal and health economic perspective, ILIT might constitute a new 
paradigm in allergen-specific immunotherapy as the treatment requires fewer 
treatment visits, fewer injections and considerably lower allergen doses than 
conventional SCIT. 
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SUMMARY AND CONCLUSIONS 
¾ A differentiated expression of NOD1, NOD2, NALP1, NALP3 and NAIP was 
found in tonsillar and blood-derived B lymphocytes. The expression was 
generally higher in peripheral B cells. Stimulation with the NOD1 and NOD2 
agonists alone failed to induce B cell activation but concomitant triggering of 
the BCR increased proliferation, induced expression of cell surface markers and 
prolonged survival. Peripheral B cells were activated by the NOD1 and NOD2 
ligands, whereas tonsil-derived B lymphocytes responded solely to NOD1. 
Additionally, NLR ligands were found to enhance TLR-induced proliferation of B 
cells, whereas co-stimulation via CD40L failed to induce activation. 
 
These results indicate that during infection, B lymphocytes can recognize 
pathogens via NLRs, which point to a mechanism ensuring effective clearance 
of microbes by bridging innate and adaptive immunity. 
 
¾ Tonsillar T lymphocytes expressed a broad range of NLRs and RLRs, comprising 
NOD1, NOD2, NALP1, NALP3, NAIP, IPAF and RIG-I, MDA-5 and LGP-2, 
respectively. Stimulation with the NOD1, NOD2 and RIG-I/MDA-5 ligands in 
combination with TCR triggering induced proliferation, enhanced secretion of 
IL-2 and IL-10 and up-regulated expression of CD69 of tonsillar mononuclear 
cells. In purified tonsillar CD3+ T cells, stimulation of the TCR promoted 
proliferative responses but they were not further enhanced by the cognate 
ligands. 
 
These data support the idea of an important role of innate immune receptors 
in the adaptive branch of the immune system. Also, T cells appear to play a role 
in the response towards bacterial and viral infections.  
 
¾ Prominent expression of NOD1 and NOD2 along with low levels of RIG-I and 
MDA-5 was found in eosinophils. Stimulation with the NOD1 and NOD2 ligands 
induced activation mediated via the NF-κB pathway. This was evidenced by 
secretion of IL-8, prolonged survival, regulated expression of cell surface 
markers and chemotactic migration. The NOD2 ligand also increased secretion 
of EDN and NOD1- and NOD2-induced activation was augmented by IL-5 and 
GM-CSF, but not by IFN-γ. 
 
These findings suggest the NLR system as a new pathway for eosinophil 
activation and as the responses are enhanced in the presence of cytokines 
regulating Th2 immunity, the NLRs might have a role in linking respiratory 
infections with allergic diseases. 
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¾ ILIT was found to be safe for the patients and none of the injections elicited 
any severe adverse events. Among patients receiving active treatment, 
increased levels of allergen-specific IgE and induced peripheral T cell activation 
were seen. A clinical improvement of nasal allergic symptoms upon challenge 
was recorded along with a decreased inflammatory response in the nose as 
characterized by lowered levels of IL-8 and reduced levels of inflammatory cells 
in nasal lavage fluids. Additionally, the patients reported an improvement of 
their seasonal allergic disease. No such changes were seen in the placebo 
group. 
 
Our data highlight ILIT as a safe and effective administration route for 
treatment of pollen-induced allergic rhinitis and this treatment strategy might 
constitute a less time-consuming and more cost-effective alternative to 
conventional SCIT. 
 
 
¾ On a cellular level, active ILIT enhanced activation of granulocytes and reduced 
activation of Th2 lymphocytes and regulatory T lymphocytes. Among actively 
treated patients reporting successful treatment and improvement of their 
allergies, reduced symptoms upon challenge were demonstrated in 
combination with reduced use of pharmaceutical treatment products.  
 
These results indicate that the clinical effects of ILIT are accompanied by 
alterations in the activation profiles of peripheral leukocytes and reveal new 
insights on mechanisms underlying the beneficial effects of the treatment. 
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FUTURE PERSPECTIVES 
One of the key findings in immunology research was the essential role of PAMP 
recognition by PRRs in the induction of immune responses made by Charles 
Janeway 110. Since then, these receptors have been extensively studied and new 
insights about their diverse roles in health and disease are constantly being 
provided. It is now apparent that the PRRs are important in the induction of both 
innate and the adaptive immunity and we amongst others have demonstrated roles 
in eosinophils, neutrophils and epithelial cells as well as in B and T lymphocytes 12-17, 
23, 111. Therefore, it seems reasonable that the two branches of the immune system 
should be viewed as complementary and cooperating.  
In most studies, one PRR in a specific cell type in a certain environment has been 
investigated, but in order to fully understand the complex roles of PRRs, the 
interaction between various PRR members, cells and mediators needs to be 
assessed. Single-cell systems in which an isolated cell type is stimulated via a single 
receptor by a specific agonist poorly represent the natural biological environment. 
Therefore, advances in the area of cooperation between different PRRs are likely of 
importance. Interestingly, synergistic effects between NLRs and TLRs were observed 
in B lymphocytes, which strengthen the idea that the combined actions of the 
receptor families are needed to ensure effective clearance of infections. Failure in 
this defense can, during certain circumstances, lead to the development of allergic 
diseases and also promote exacerbations of allergic diseases. The presented relation 
between PRRs and Th2-promoting cytokines in eosinophils seems to corroborate 
such a notion. However, the link between microbes, PRRs and allergy will need to be 
further explored.  
Upon infection or an allergic reaction, microbial components or allergens are 
effectively drained to secondary lymphoid organs where adaptive responses are 
initiated. When this process is mimicked in terms of delivery of allergen directly to 
the lymph node during the course of ILIT, protective immune responses are quickly 
induced. Already after three injections tolerance against alum-adjuvanted allergens 
can be observed but the mechanisms behind these beneficial effects need to be 
further dissected. PRRs might play a role in this process as the immunostimulatory 
properties of Alum recently have been attributed to the interaction with the NALP3 
inflammasome 21, 22. Indeed, the PRR system is being extensively utilized in the 
development of new types of vaccines based on its ability to skew the immune 
system in the desired direction. 
As compared to SCIT, ILIT has a better safety profile, requires considerably lower 
allergen doses but also fewer treatment visits and allergen injections. This opens up 
for greater flexibility for the patients but also creates new opportunities for 
dissection of the protective mechanisms behind allergen-specific immunotherapy. 
From a socioeconomic perspective, the benefits of ILIT stand clear. In Sweden, the 
entire ILIT protocol with three injections is estimated to cost approximately 800 
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EUR/patient and allergen. This could be compared to approximately 9000 
EUR/patient and allergen for SCIT which requires more than 50 injections over a 4 
year period 112. To this, the indirect costs associated with the long SCIT treatment 
need to be added. In addition to providing a safe and effective treatment route for 
allergic diseases, ILIT might therefore represent a new paradigm in allergen-specific 
immunotherapy.  
Taken together, we hope that the results presented in this thesis can constitute a 
foundation for using PRRs and ILIT in the development of new and more effective 
treatment strategies for inflammatory airway diseases and for prevention of allergic 
exacerbations.  
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